The ARCADIA trial (Alleviation of cardioRespiratory complications in patients with COVID-19 And DIAbetes) using AZD1656

使用 AZD1656 的 ARCADIA 试验（减轻 COVID-19 和糖尿病患者的心肺并发症）

• 批准号: 72965
• 金额: $ 421.02万
• 依托单位: ST GEORGE STREET CAPITAL
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=72965
• 关键词: ARCADIA; trial; Alleviation; cardioRespiratory; complications

SGS is looking to run a clinical trial using a new drug, AZD1656 to treat diabetic patients suffering with COVID-19\. The potential drug AZD1656 was originally being explored for renal transplant rejection but it is hypothesised that the same mechanism of reducing excessive inflammation by the immune system could equally apply to those with severe coronavirus infection. Clinical observations have shown people with coronavirus can go through two stages of the disease. The first stage is an appropriate response of the immune system to fight the viral infection. In many people this is successful, and patients start to feel better after a week. In some people however the immune system overreacts, and they enter a second stage of the disease called 'hyperinflammation', where the body's own immune system starts to damage vital organs such as the lungs. Our potential treatment for COVID-19 aims to use the body's own mechanism of controlling excess inflammation by activating T regulatory cells. These T regulatory cells migrate to sites of inflammation such as the lungs, effectively dampening down the excess inflammation to reduce organ damage. In addition, AZD1656 has been shown to reduce blood glucose in patients with diabetes in clinical trials. Patients with both type I and type II diabetes are believed to be at higher risk of having more severe COVID-19 symptoms due to a number of biological factors, with blood glucose control being an important one. St George Street is aiming to start the clinical trial in July 2020, a vastly accelerated timescale driven by the urgency of the current pandemic. AstraZeneca will supply the formulated drug product at no cost to SGS and SGS will lead the clinical trial, enrolling 150 patients in hospitals in the UK over a 3-month timeframe. The primary objective of the trial through treating patients with AZD1656 is to reduce the number of diabetic patients with COVID-19 who decline and progress to the ICU.

SGS正在寻求使用新药AZD 1656进行临床试验，以治疗患有COVID-19的糖尿病患者。潜在的药物AZD 1656最初被探索用于肾移植排斥反应，但假设免疫系统减少过度炎症的相同机制同样适用于严重冠状病毒感染的患者。临床观察显示，冠状病毒感染者可以经历两个阶段。第一阶段是免疫系统的适当反应，以对抗病毒感染。在许多人中，这是成功的，患者在一周后开始感觉更好。然而，在一些人中，免疫系统反应过度，他们进入疾病的第二阶段，称为“炎症过度”，身体自身的免疫系统开始损害重要器官，如肺部。我们对COVID-19的潜在治疗旨在利用身体自身的机制，通过激活T调节细胞来控制过度炎症。这些调节性T细胞迁移到炎症部位，如肺部，有效地抑制过度炎症，以减少器官损伤。此外，在临床试验中，AZD 1656已被证明可以降低糖尿病患者的血糖。据信，由于多种生物因素，I型和II型糖尿病患者出现更严重COVID-19症状的风险更高，其中血糖控制是一个重要因素。圣乔治街的目标是在2020年7月开始临床试验，由于当前大流行的紧迫性，这一时间表大大加快。阿斯利康将免费向SGS提供配方药物产品，SGS将领导临床试验，在英国的医院招募150名患者，为期3个月。通过AZD 1656治疗患者的试验的主要目的是减少患有COVID-19的糖尿病患者的数量，这些患者下降并进展到ICU。